April 22, 2024

CDMO Live 2025

CDMO Live 2025
Go back

CDMO Live 2025 is a premier conference dedicated to the future of contract development and manufacturing in the biopharmaceutical industry. Scheduled for May 7–8, 2025, at the Rotterdam World Trade Center, the event brings together key stakeholders, including executives from pharmaceutical and biotechnology companies, contract manufacturing organizations (CMOs), and contract development and manufacturing organizations (CDMOs).

The event provides a highly focused networking platform, enabling attendees to engage in PartnerMatch meetings, fostering collaborations and business development opportunities. The conference agenda covers small molecules, biologics, and advanced therapies, including cell and gene therapy, with expert-led sessions addressing the latest trends, regulatory challenges, and technological innovations in contract manufacturing.

CDMO Live 2025 also features panel discussions, keynote presentations, and interactive sessions designed to help industry professionals stay ahead in the evolving landscape of drug development and manufacturing.

ALL BioRN members receive s a 15 % discount.
Complimentary passes for approved member companies.

Please contact Nicole Hecht (nh(at)biorn.org) for the Discount Code and more Information.

register now

Our latest News

discover more
Helping children with cancer with flowers

Helping children with cancer with flowers

From April 28 to May 24, you can once again buy and give flower creations throughout Germany for the benefit of children and young people with cancer. With its campaign “Blumen schenken. Hoffnung spenden.” (Give flowers. Spread hope.) the Hopp Children’s Cancer Center Heidelberg (KiTZ) wants to draw attention to the urgently needed research for […]

read more
Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed/refractory multiple myeloma

Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed/refractory multiple myeloma

GSK plc (LSE/NYSE: GSK) today announced the authorisation of Blenrep by the Medicines and Healthcare products Regulatory Agency (MHRA). In the UK, Blenrep is approved for the treatment of adults with multiple myeloma in combination with bortezomib plus dexamethasone (BVd) in patients who have received at least one prior therapy, and in combination with pomalidomide plus dexamethasone (BPd) in […]

read more
New regulatory protein of the neuronal cytoskeleton identified

New regulatory protein of the neuronal cytoskeleton identified

The growth and function of nerve cells is based on a lattice-like structure called membrane-associated periodic skeleton (MPS). However, how the organization of the MPS is controlled has not been elucidated until now. A team from the Max Planck Institutes for Medical Research and for Multidisciplinary Sciences has now discovered that it is regulated by […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp